Brendan Kelly is a Principal at Lightstone Ventures who combines hands-on medicinal chemistry and computational drug discovery research experience from Trinity College Dublin, University of Toronto, and Stanford with venture investing, plus first-hand company formation experience as founder of A2a Pharmaceuticals. His academic background includes peer-reviewed publications in Cell, J. Med. Chem., JACS, and eLife on drug discovery topics, allowing him to evaluate biotech platforms and targets as a former publishing scientist rather than just a financier.